What is Luminopia?
Founded in 2016, Luminopia operates at the intersection of digital health and ophthalmology, pioneering a new class of treatments for significant neuro-visual disorders. The company is dedicated to developing digital therapeutics that are both rigorously evaluated for FDA approval and engaging for patients. As an Innovation Partner of Boston Children's Hospital, Luminopia is advancing its lead product, Luminopia One, which is specifically designed to improve vision in children with amblyopia, the leading cause of vision loss among children. By integrating clinical efficacy with patient-centric design, the firm is establishing a new standard for non-invasive, software-based medical interventions.
How much funding has Luminopia raised?
Luminopia has raised a total of $26.5M across 2 funding rounds:
Angel/Seed
$10.5M
Series A
$16M
Angel/Seed (2022): $10.5M with participation from Sony Innovation Fund, The Vertical Group, ShangBay Capital, and SSI Strategy
Series A (2023): $16M led by Broadfin Capital, ShangBay Capital, and U.S. Venture Partners
Key Investors in Luminopia
Broadfin Capital
A healthcare-focused investment firm founded in 2005 that specializes in unique investment opportunities and comprehensive asset allocation within the medical sector.
ShangBay Capital
A Palo Alto-based venture capital firm specializing in medical devices, biotechnology, and early-stage healthcare innovation.
U.S. Venture Partners
A prominent Silicon Valley firm that partners with entrepreneurs to build transformative companies, with a deep focus on healthcare and enterprise software.
What's next for Luminopia?
Looking ahead, Luminopia is poised to leverage its recent capital infusion to scale its commercial operations and deepen its clinical pipeline. The company's strategic roadmap focuses on expanding the accessibility of its digital therapeutics, ensuring that its FDA-cleared solutions reach a broader patient demographic. Furthermore, the firm is expected to continue its collaborative research efforts with leading medical institutions to validate the efficacy of its platform across additional neuro-visual indications. As the digital therapeutics market matures, Luminopia's commitment to rigorous clinical evidence and strategic partnerships will be instrumental in maintaining its competitive advantage and driving long-term value for stakeholders in the medical device and biotechnology sectors.
See full Luminopia company page
